Therapy Areas: Oncology
BGI Genomics announces Zentya partnership to Launch Fecal DNA Test for Colorectal Cancer in Slovakia
30 March 2023 -

China-based genomic research organisation, BGI Genomics, announced on Wednesday the launch of COLOTECTTM 1.0 in Slovakia, in collaboration with its partner, Zentya, a Slovak-based company involved in providing patients with the latest technology in genetic screening.

COLOTECTTM 1.0 is one of the first-ever faecal DNA tests for colorectal cancer that is available in Slovakia. It is a non-invasive faecal DNA test for detecting colorectal cancer and precancerous lesions. It uses multiplex methylation-specific PCR technology to trace abnormal colorectal cancer DNA-methylation biomarkers from fecal samples.

A product launch press conference was held in Bratislava, Slovakia. Dr Martin Huroka (chief gastroenterology specialist, Ministry of Health), Dr Lucia Starovecka Copak (medical geneticist), and Dr Jozef Dolinsky (clinical oncologist), were the invited speakers.

Early detection is the key to the prevention of colorectal cancer and the improvement of survival rate because the progression of colorectal cancer development is generally very slow. It can take 10 to 15 years to develop from normal epithelium to adenomatous polyps and then undergo malignant transformation to become colorectal cancer.

Login
Username:

Password: